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Medicinal plants are recognized as sources of natural antioxidants that can protect from biological
system oxidative stress. The present cross-sectional before/after clinical trial was carried out to investi-
gate the antioxidant properties of the decoction of the flowers of Echium amoenum Fisch & C.A. Mey in
humans. A group of 38 healthy subjects was invited to use the E. amoenum (7 mg kg
 1) twice daily for
14 days. Blood samples before and after entering the study were measured for lipid peroxidation level
(LPO), total antioxidant capacity (TAC) and total thiol (SH) molecules. A significant reduction of blood
LPO (24.65 ± 11.3 versus 19.05 ± 9.7, P ¼ 0.029) was observed after 14 days of E. amoenum con-
sumption. Blood TAC (1.46 ± 0.51 versus 1.70 ± 0.36, P ¼ 0.018) and total thiol molecules
(0.49 ± 0.11 versus 0.56 ± 0.12, P ¼ 0.001) increased after 14 days of E. amoenum consumption. In
conclusion, this antioxidative stress potential of E. amoenum may be due to its bioactive antioxidant
components, especially rosmarinic acid and flavonoids. In recent years the importance of oxidative
stress in the pathophysiology of many human disorders has been confirmed, thus use of this plant as a
dietary supplement is highly recommended.
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Introduction
Free radicals, like reactive oxygen species (ROS), nitrogen
(RNS) and chlorine (RCS), are normal by-products of meta-
bolism and they are introduced into the body from outside
sources of harmful chemicals in the environment, unhealthy
foods, stress, certain drugs, cigarette smoke, etc. Increasing
the intake of antioxidants can neutralize free radicals and pro-
tect the body from cell damage. In the body, oxidative stress
results from the imbalance between the extent of ROS forma-
tion and the antioxidant defense mechanisms. Links between
oxidative stress and adverse health effects have been suggested
for several groups of diseases, including cardiovascular,
respiratory and neurological as well as for the general aging
process. Such adverse effects are mediated by free radical
damage to lipids, proteins and DNA. Protection from damage
occurs through the action of multiple antioxidants, some
endogenously produced and some provided through dietary
intake (1–3). It is believed that medicinal plants are a potential
source of antioxidants and ROS scavenger molecules (4).
One of these plants is Echium amoenum Fisch & C.A. Mey
that has been shown as a rich source of antioxidants, like
rosmarinic acid (RA) and flavonoids. This plant belongs to
the Boraginaceae family and is a biennial or perennial herb
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Caucasus, where it grows at highlands at the altitude ranging
from 60 to 2200 m (5).
There has been an increased interest in Echium species,
including E. amoenum (F.M.), because of their medicinal and
nutritional properties. E. amoenum (F.M.) is one of the most
important medicinal plants in Iranian traditional medicine
(6). The flowers of this plant have been used as demulcent,
anti-inflammatory and analgesic, anxiolytic, and sedative in
folk medicine of Iran (5–7). Anxiolytic effect of the flower
of this plant has been shown in two separate experimental
studies in mice (8,9). In Western medicine, the flowers and
the leaves of borage have been similarly used as antifebrile,
antidepressant, anxiolytic, ameliorant of heart and pulmonary
disturbances, poultice for inflammatory swellings, diuretic,
laxative, emollient and demulcent, and recently as a possible
protective factor against cancer (10–12). Extract of this plant
has been shown to contain flavonoids, saponins, unsaturated
terpenoids and sterols (8). Extract of Eqium was effective at
intraperitoneal doses of 80–125 mg kg
 1 in animals (10) and
has not been toxic in doses as high as 6 g kg
 1 (13).
Phytochemical studies on E. amoenum revealed the presence
of many chemicals such as RA, anthocyanidine, flavonoids,
g-linolenic acid and trace amount of alkaloids (6,14,15). The
antioxidant properties of flavonoids (16,17) and RA (18–22)
have been well established.
Regarding the above-mentioned information, we were
interested in performing a cross-sectional before/after clinical
trial study to explore antioxidant influences of E. amoenum
(F.M.) in human by evaluation of blood total antioxidant
capacity (TAC), lipid peroxidation (LPO) and total thiol
(SH) molecules.
Subjects and Methods
Study Design
A clinical trial study with a total of 38 subjects was designed.
Subjects were volunteer students of Arak University of
Medical Sciences, located in the south-west of Iran, who all
lived in the university dormitory. Subjects were selected on a
simple random basis from volunteers. The study was con-
ducted in complete accordance with the declaration of
Helsinki. All participants were provided with specific written
consents obtained prior to entrance into the study. Each indi-
vidual was extensively interviewed by a specialized physician
who filled in a structured questionnaire specifying gender,
smoking, dietary habits, sports habits and history of special
disease, before obtaining blood. Then the subjects were
Figure 1. Effect of the consumption of E. amoenum (F.M.) decoction (7 mg
kg
 1, twice per day for 14 days) on blood lipid peroxidation (LPO) level in
healthy subjects (n ¼ 38). Results are expressed as mean ± SE. P-value is rep-
resented in graph.
Figure 3. Effect of the consumption of E. amoenum (F.M.) decoction (7 mg
kg
 1, twice per day for 14 days) on blood total thiol molecules in healthy sub-
jects (n ¼ 38). Results are expressed as mean ± SE. Significance difference in
P-value is represented in graph.
Figure 2. Effect of the consumption of E. amoenum (F.M.) decoction (7 mg
kg
 1, twice per day for 14 days) on blood total antioxidant capacity (TAC)
in healthy subjects (n ¼ 38). Results are expressed as mean ± SE. P-value is
represented in graph.
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(7 mg kg
 1) twice daily (morning and evening) for 2 weeks.
The dose was selected on the basis of a pilot study and
traditional use information. A supervisor carefully checked
to make sure that the volunteers were taking the decoction
properly. Demographic characteristics of the subjects are
presented in Table 1.
Materials
5,50-Dithiobis-2-nitrobenzoic acid (DTNB), Tris base,
1,1,3,30-tetraethoxypropane (MDA) from Sigma, UK,
2-thiobarbituric acid (TBA), trichloroacetic acid (TCA), n-
butanol from Merck, Germany, and 2,4,6-tripyridyl-s-triazine
(TPTZ) from Fluka, Italy, were used in this study.
Plant Material
Flowers of E. amoenum (F.M.) were collected from a farm at
80 km north of Ghazvin (a city in western Iran) in June 2002.
A total of 450 g air-dried flowers of E. amoenum was used to
provide the decoction.
Plasma Preparation
Five milliliters of heparinized blood was collected from each
subject at the end of the 2 week treatment, centrifuged at
1200 g for 10 min at 4 C and plasma freezed at  80 C until
analysis. Blood samples were collected 12 h after the last
dose of decoction was taken.
Measurement of Plasma TAC
Antioxidant capacity of plasma was determined by measuring
the ability of plasma to reduce Fe
3þ to Fe
2þ. The complex
between Fe
2þ and TPTZ gives a blue color with absorbance
at 593 nm (23).
Measurement of Plasma Total Thiol Molecules
Total sulfhydryl content was determined in plasma by the
method of Hu (24). A volume of plasma (0.20 ml) was mixed
in a 10 ml test tube with 0.6 ml of Tris–EDTA buffer (Tris base
0.25 M, EDTA 20 mM, pH 8.2) followed by the addition of
40 ml of 10 mM of DTNB in methanol. The final volume
of the reaction mixture was made up to 4.0 ml by adding
3.16 ml of methanol. The test tube was capped, and the color
was developed for 15–20 min, followed by centrifugation at
3000 g for 10 min at ambient temperature. The absorbance of
the supernatant was measured at 412 nm.
Measurement of LPO
LPO of plasma was determined by the reaction of TBA with
MDA and other lipid peroxides. Briefly, plasma samples
were mixed with TCA (20%) and the precipitate was dispersed
in H2SO4 (0.05 M). TBA (0.2% in sodium sulfate) was added
and heated for 30 min in a boiling water bath. LPO adducts
were extracted by n-butanol and absorbance was measured at
532 nm (25).
Statistics
Paired t-test was used to analyze the significance of differences
observed between study groups. F-test was used to determine
the normal distribution of variances between groups. P-values
>0.05 were considered insignificant.
Results and Discussion
A significant decrease (P < 0.05) in LPO was observed by use
of E. amoenum. The mean ± SD before and after using were
24.65 ± 11.33 and 19.05 ± 9.7 nmol ml
 1 (Fig. 1). After use
of the decoction, the TAC level increased significantly
(P < 0.05). The mean ± SD values before and after were
1.46 ± 0.51 and 1.70 ± 0.36 mmol ml
 1 (Fig. 2). A significant
(P < 0.001) increase in total thiol molecules was observed
after administration of the decoction (0.49 ± 0.11 mmol ml
 1
before versus 0.56 ± 0.12 mmol ml
 1 after (Fig. 3).
The Consumption of E. amoenum Markedly Decreases
ROS Concentrations
In this study, the influence of usage of the decoction
(7 mg kg
 1) twice daily (morning and evening) for 2 weeks
on the oxidative stress status of healthy subjects was studied.
Results indicate that TAC and thiol groups increased and
LPO as a marker of ROS concentration markedly decreased
after consumption of E. amoenum. In the body, antioxidants
act as free radical scavengers and thus protect cells from being
exposed to free radicals and further cellular damage. This is
the mechanism by which they protect the human body from
several diseases attributed to the reactions of radicals. Numer-
ous substances have been suggested to act as antioxidants in
this plant. Various phenolic antioxidants such as flavonoids,
RA, tannins, coumarins, xanthenes and, more recently, pro-
cyanidins have been shown to scavenge radicals in a dose-
dependent manner (26,27). In addition, flavonoids and RA
have been introduced as the main constituents of E. amoenum
(F.M.) in several phytochemistry studies (6,16,17,27,28).
Table 1. Demographic characteristics of study subjects
Using drug Sport Smoking Age (year) Sex Number of
subjects No Yes No Yes No Yes Female Male
33 (86.8%) 5 (13.2%) 25 (65.8%) 13 (34.2%) 38 (100%) 0 18–25 25 (65.8%) 13 (34.2%) 38
eCAM 2006;3(4) 471The antioxidant potential of flavonoids has been well
established (22,23). Flavonoids can highly scavenge most
types of oxidizing molecules, including singlet oxygen and
various free radicals, and thus act indirectly as an efficient
antioxidant (29). They can also act directly by suppressing
ROS formation (30).
RA Reduced Pro-inflammatory Molecule Expression
and Enhanced Antioxidative Activity
RA, the other important constituent of this plant, is an ester of
caffeic acid and 3,4-dihydroxyphenylacetic acid. It is com-
monly found in species of the Boraginaceae and the subfamily
Nepetoideae of the Lamiaceae. There are a number of reports
on the antioxidative activities of RA which all confirm that
RA has strong antioxidant activity even higher than vitamin
E. In this regard, the reported positive effects of RA include
enhancement of superoxide and hydroxyl scavenging (20),
inhibition of both low-density lipoprotein (21) and oil oxida-
tion (19), suppression of arachidonate metabolism formation
(31), inhibition of hemolysis (32), and having hyaluronidase
and h-hexosaminidase activities (33). In addition, RA inhibited
lung injury in mice that is regularly induced by diesel exhaust
particles. RA showed this by reduction of pro-inflammatory
molecule expression and enhanced antioxidative activity (34).
In conclusion, the present findings well indicate that
E. amoenum (F.M.) decoction has very good potential to
improve human antioxidant status and prevent normal oxidat-
ive stress that happens daily due to normal exposure to many
causal chemicals and conditions. This potential of E. amoenum
(F.M.) seems to be due to its bioactive antioxidant compon-
ents, especially RA and flavonoids. In recent years the import-
ance of oxidative stress in the pathophysiology of many human
disorders has been highlighted (35–44), thus use of this plant
as a dietary supplement is highly recommended (45,46). Trials
to establish efficacy and optimum dosage of the present
herbal product for treating human chronic diseases with patho-
physiology of oxidative stress are essential.
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